This week in The Wall Street Journal: Clairity, Inc. is featured for its groundbreaking AI model designed to predict breast cancer risk from a routine mammogram. Clairity’s technology goes beyond diagnosis to support proactive, preventive care. Trained on more than 400,000 mammograms, its AI can identify subtle patterns in breast tissue that even expert radiologists cannot see - helping physicians determine if a patient may need additional screening or preventive treatments. With FDA authorization secured back in May, Clairity plans to introduce this first-of-its-kind tool in U.S. clinics later this year. At Santé, we are proud to support Clairity as it advances AI-driven innovation with the potential to transform women’s health. https://lnkd.in/efKYB3ki
We’re honored that Clairity, Inc.’s work is featured by Brianna Abbott in the The Wall Street Journal. The article highlights how our FDA-authorized AI model can analyze a routine mammogram to estimate a woman’s five-year risk of breast cancer. This represents a major step forward from traditional tools like family history or breast density, which often miss many women at risk. Clairity Breast is the first and only FDA-authorized image-only AI model for 5-year breast cancer risk prediction. Trained on more than 400,000 mammograms and validated across diverse U.S. populations, it provides clear and equitable risk information that women and providers can trust to guide prevention and early detection. https://lnkd.in/dMV2wvgA